Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer, Rheonix, Genetic Signatures, More

NEW YORK – Rheonix said this week that it has opened a CLIA-certified clinical laboratory near the company's headquarters in Ithaca, New York. Rheonix Laboratories has New York state authorization to provide COVID-19 testing and results and will be partnering with organizations such as pharmacies, schools, long-term care facilities, and county and municipal health departments to provide low-cost testing. The laboratory specifically provides the Rheonix COVID-19 MDx assay, which was granted US Food and Drug Administration Emergency Use Authorization in April 2020

PerkinElmer last week declared a quarterly dividend of $.07 per share of its common stock. The dividend will be payable on Nov. 11 to all stockholders of record as of the close of business on Oct. 21. 

Genetic Signatures of Australia said this week that it had A$4.9 million (US$3.4 million) in revenues for Q4 of its fiscal year 2022, which ended June 30, down 10 percent from A$5.4 million in Q4 of FY2021. The firm attributed the downturn to a decrease in SARS-CoV-2 molecular testing in both Australia and international markets. Genetic Signatures did not report net income or loss for the quarter. For fiscal year 2022, the company reported A$35.4 million in sales, up 25 percent from A$28.3 million in FY2021. As of June 30, Genetic Signatures held A$36.9 million in cash. 

ProPhase Labs said this week that its board of directors has authorized a stock repurchase program of up to $6 million. The program will become effective three days after Garden City, New York-based ProPhase reports its second quarter 2022 earnings on Aug. 12. Following that date, and for six months thereafter, repurchases may be made through open market transactions, privately negotiated transactions, block trades, or any combination thereof, in accordance with applicable federal securities laws. 

Diagnostics firm Inex Innovate of Singapore said this week that it has provided an undisclosed amount of funding to researchers at the Chinese University of Hong Kong (CUHK) to further develop Inex’s fetal cell isolation and enrichment technology, Lexi, for noninvasive prenatal testing. The Lexi technology uses a microfluidic chip with a microfabricated filter to deplete most non-target cells in a blood sample and capture fetal cells. The funding will support research by Richard Choy, a professor in the department of obstetrics and gynecology at CUHK. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.